The INKEY List Salicylic Acid Cleanser: three documents, one exact product

The exact manufacturer heading identifies Salicylic Acid Cleanser in a 150 mL size. The page describes a lightweight gel texture. Its comparison block separately names 360° Acne Clearing Serum and lists a different set of highlighted actives for that item. Those serum details cannot be added to the cleanser’s formula. Exact cleanser and comparison blocks.

The distinction is useful before evaluating any claim. A nearby product may share a familiar ingredient while having a different name and role. Our version-and-label guide keeps those identities attached to their own records. This review consequently treats the gel description as a product-identification fact, not as proof of superior cleansing, equal exposure to a serum or suitability for a person’s skin.

The US labeling record calls the product a salicylic-acid gel and identifies 2% salicylic acid with an acne-treatment purpose. Its inactive list includes water, propanediol, glycerin, zinc PCA, allantoin and other named components. This is a full posted panel, rather than a reconstruction from the page’s three highlighted ingredients. Cleanser label.

FDA explains that active, purpose, uses, warnings and inactive ingredients have different roles in Drug Facts. That distinction helps readers understand the gel without assigning a function or quantity to every ingredient themselves. The identity, ingredients and warnings here derive from one posted labeling version; they are not three independently acquired corroborating labels. FDA field explanation.

A separate manufacturer page describes a four-week consumer trial involving 66 people with oily and acne-prone skin. It attributes the trial to a third party. Its summaries report participant agreement about clarity, oil appearance and comfort, including 92% saying skin did not feel tight or stripped over the trial. These remain the brand’s account of the study. Consumer-trial summary.

The full report was not acquired, so the account cannot establish the complete protocol, comparison design or experience of every future user. Nor should the trial’s time points become instructions about when another person must improve. The 2% comparison guide explains why a specification and a reported outcome still require different evidence.

The current product page shows many customer reviews and explicitly labels one summary as AI-generated from recent reviews. That material is separate from the 66-person trial. The manufacturer’s trial page also includes a buyer’s description of nose-pore appearance; a testimonial is not automatically one of the trial’s measured endpoints. Review-summary wording and trial-page testimonial.

The distinction matters even when the accounts sound consistent. Review totals do not supply a study denominator, and favorable personal comments do not reveal a controlled comparison. Keeping each source genre visible allows the published trial summary to be considered without treating the page’s popularity, automated synthesis and personal stories as interchangeable clinical proof.

The fresh US page pairs $15 with 150 mL. Its shipping section describes different state-based rates, a free-shipping threshold and exclusions. It also expressly calls its delivery timelines estimates rather than guarantees. These are manufacturer terms observed on the page, not the result of completing an order. Current price and shipping record.

FDA distinguishes net contents from other product fields, which helps explain why an identified bottle is not a verified period of treatment. The supply-term discussion follows the same principle for different commercial units. This review does not turn the bottle price into a monthly cost, calculate an individual quantity or certify the final taxes and shipping applicable to an untested checkout. Quantity fields.

The product page promises a clean, balanced feel without stripping. The posted label warns that using another topical acne medication can make dryness and irritation more likely. The warning belongs to the same cleanser record; supportive descriptions of zinc or allantoin do not remove it. Manufacturer comfort wording and posted warning.

AAD gives broader context for dryness with salicylic-acid acne treatment. It does not assess this particular cleanser for an individual or authorize a combination of products. A useful reading preserves both the manufacturer’s reported comfort and the label’s limitation, while leaving a personal concern to the appropriate professional rather than inventing a routine from the website. AAD context.

The labeling entry identifies Brand Evangelists for Beauty, a March 2025 revision and version 5. Its package table includes the 150 mL bottle as well as a separately described packet. The record therefore offers more precise identification than the brand name alone, without proving which version a retailer will send. Version and package table.

FDA cautions that NDC assignment is not approval or verification of the submitted content. The identifier remains useful for locating a record. Readers can continue with the COSRX review and Peach Slices review as separate entries. The remaining question here is which package and evidence report describe the actual cleanser under discussion. NDC explanation and label-change context.